

Supplementary Material

Results of neutralization assays of Metadichol performed with HEK 293T-ACE2, a human embryonic kidney cell line over expressing ACE2, the receptor of SARS-CoV-2 virus.

Neutralization Activity Metadichol® Against SARS-CoV-2 Pseudovirus

Background to Neutralization assay

Source: <https://bpsbioscience.com/ace>

Commercial contract work outsourced by a service provider;

Retrovirox, Inc San Diego USA

In Viral replication, the virus attaches to the host cell surface before entering the cell. The

| SARS-CoV2 Pseudovirus | | | | VSVg Pseudovirus | | | viral Spike protein |
|-----------------------|--------------|------------|-------|------------------|------------|-------|---------------------|
| Sample | IC50 (µg/mL) | Assay S/B* | C.V.# | IC50 (µg/mL) | Assay S/B* | C.V.# | |
| metadichol | 6.7 | 538 | 1.7% | 3.4 | 297 | 1.0 | |

recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection.

The SARS-CoV-2 Spike Pseudo-typed Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity


Neutralization assays were performed using a non-replicative VSV pseudovirus with a firefly luciferase reporter gene and also carrying the spike protein of SARS-CoV-2 (SARS-CoV-2/VSV-Luc pseudovirus). Metadichol was evaluated with a similar VSV pseudovirus reporter carrying the envelope glycoprotein (VSVg) of the vesicular stomatitis virus (VSVg/VSV-Luc pseudovirus).

The neutralization assays were performed with HEK 293T-ACE2, a human embryonic kidney cell line overexpressing ACE2, the receptor of SARS-CoV-2 virus. Test-item was pre-incubated for 60 min at 37°C with a previously titrated inoculum of pseudovirus. Then, the mixture was added to 293T-ACE2 cells. Twelve hours later one volume of complete tissue culture media (DMEM supplemented with 10% FBS) was added to the cells. Neutralization of pseudovirus entry was determined by measuring firefly luciferase activity (RLUs) 12h after addition of media (24h post-infection). Putative neutralizing agents were present in the cell culture for the duration of the experiment. Eight concentrations of the Metadichol samples were tested in duplicates utilizing 10-fold serial dilutions started at 10µg/mL.

Neutralization Activity of Test-Item metadichol

At the highest concentration tested (10µg/mL) metadichol inhibited infection with VSV pseudoviruses carrying SARS-CoV-2 spike. The IC₅₀ neutralization values for the test-item is shown in Table 1 below.

Inhibitors and Quality Controls



Determination of IC₅₀ values for pseudovirus entry. Values indicate the percentage of SARS-CoV-2/VSV-Luc or VSVg/VSV-Luc pseudovirus neutralization as compared to samples incubated with no test-item (DMEM 2% FBS, “vehicle alone”). Results show the average of duplicate data points. Data was adjusted to a sigmoid function and IC₅₀ values were calculated using

Quality controls for the pseudovirus assays were performed on every plate to determine: i) signal to background (S/B) values; ii) inhibition by a known inhibitor of SARS-CoV-2 entry, and iii) variation of the assay, as measured by the coefficient of variation (C.V.) of all data points.

All controls worked as anticipated for each assay. A recombinant form of the spike glycoprotein receptor binding domain (RBD) from SARS-CoV-2 (Wuhan-Hu-1) neutralized SARS-CoV-2 VSV pseudovirus (76 percent inhibition when tested at 25µg/mL). A rabbit polyclonal antiserum against a truncated form of SARS-CoV spike protein also neutralized SARS-CoV-2 VSV pseudovirus (67 percent inhibition when tested at 1:80 dilution). By contrast, the recombinant spike protein diminished infection of the pseudovirus carrying VSVg by only 20 percent at the same concentration, whereas the 1:80 dilution of polyclonal anti-SARS spike displayed no inhibition on the VSVg pseudovirus.

Infection with SARS-CoV-2 or VSVg carrying pseudoviruses resulted in a luciferase signal 538-fold, or 297-fold greater than the signal generated by a similar pseudovirus lacking envelope glycoproteins (“No-Env”). When the signal of SARS-CoV-2 or VSVg carrying pseudoviruses was compared to uninfected cells, the increase was 236-fold and 358-fold, respectively. These findings demonstrate that the signal generated by the pseudovirus is the result of entry mediated by either the Spike or VSVg proteins.

Summary of Results.

IC₅₀ (neutralization) values are shown for each test-item and assay. Signal-to-background ratios (S/B), and average coefficients of variation (C.V.) of duplicate data-points for which 50% or greater infection (RLUs) was observed as compared to cells infected with pseudovirus in the absence of test-item (neutralization assay). When neutralization of pseudovirus infection was below 50% IC₅₀ values are shown as greater than highest concentration tested.

*Signal to background level was calculated by dividing the signal in uninfected cells (“mock-infected”), by the signal in cells challenged with

SARS-CoV-2/VSV-Luc or VSVg/VSV pseudovirus. #C.V. for the assays was calculated as the average of C.V. values determined for all data points displaying neutralization of 50% or greater as compared to cells infected in the presence of vehicle alone.